Forget Biogen, time to look at Neurotrope, INmune Bio - Maxim Group

NextTrip

22/03/2019 15:38

** Shares of Neurotrope  NTRP.O  up ~14 pct at $5.38 a day
after the CEO's positive comments on its Alzheimer's drug,
shares of INmune Bio  INMB.O , which is also developing a
treatment for the memory robbing disorder, up ~1 pct at $8 
    ** Neurotrope CEO's comments come after Biogen  BIIB.O  and
partner Eisai  4523.T  discontinued two late-stage trials for
Alzheimer's treatment aducanumab on Thursday  urn:newsml:reuters.com:*:nL1N2180WH
 urn:newsml:reuters.com:*:nL3N2182YI
    ** Brokerage Maxim Group calls valuation of Neurotrope and
INmune "attractive"; says both companies have "novel" approaches
to treat Alzheimer's disease 
    ** BIIB's aducanumab uses a specific mechanism to treat the
disease by targeting the beta-amyloid protein buildup in the
brains of Alzheimer's patients; brokerage says there could an
opportunity in looking more closely at other mechanisms of
action 
    ** Eli Lilly  LLY.N , AstraZeneca  AZN.L , Roche  ROG.S ,
Pfizer  PFE.N , Merck  MRK.N  and Johnson and Johnson  JNJ.N 
have all abandoned Alzheimer's drugs trials over lack of
efficacy or safety issues
    ** Including Friday's move NTRP up~32 pct this year 

 (Reporting by Aakash Jagadeesh Babu in Bengaluru)
 ((Aakash.B@thomsonreuters.com; within the U.S. +16462238780,
outside the U.S. +91  80 67491576; Reuters Messaging:
Aakash.B.thomsonreuters.com@reuters.net))